Biomarin Pharmaceutical INC 10-Q quarterly reports

BioMarin Pharmaceutical Inc. announced its Q2 2026 results, showcasing a substantial increase in net product revenues driven by the recent acquisition of Amicus Therapeutics and continued growth in key products.

BioMarin Pharmaceutical Inc. reported its first quarter 2026 financial results, highlighting increased revenues driven by key products, while also detailing significant progress and financing related to its acquisition of Amicus Therapeutics.

BioMarin Pharmaceutical Inc. reported a net loss of $30.7 million for the third quarter of 2025, primarily driven by a $221 million acquired in-process R&D expense from the Inozyme Pharma acquisition, despite strong revenue growth from key products.

BioMarin Pharmaceutical Inc. reported a significant increase in net income and revenues for the second quarter and first half of 2025, driven by strong performance across its commercial product portfolio and strategic pipeline advancements.

BioMarin Pharmaceutical Inc. announces positive Q1 2025 financial results, highlighted by a significant increase in net product revenues and net income compared to the same period last year.

BioMarin Pharmaceutical Inc. announced its third quarter 2024 results, highlighting significant revenue growth and strategic restructuring efforts.

BioMarin Pharmaceutical Inc. announced its second quarter 2024 results, highlighting revenue growth driven by VOXZOGO and progress in its research and development pipeline.

BioMarin Pharmaceutical Inc. announced its first quarter 2024 financial results, highlighted by a revenue increase driven by strong sales of VOXZOGO.